Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Lechevalier

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Genes, Chromosomes & Cancer|November 22, 2022
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significanceVictor-Emmanuel Brett, Nicolas Lechevalier, Franck Trimoreau, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Blood Cancer Journal|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry studyCamille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Blood Advances|December 24, 2019
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Genes, Chromosomes & Cancer|November 22, 2022
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significanceVictor-Emmanuel Brett, Nicolas Lechevalier, Franck Trimoreau, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Blood Cancer Journal|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry studyCamille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Blood Advances|December 24, 2019
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Pageof 2